Globus Medical Inc. Class A Common Stock vs Orion Office REIT Inc — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Orion Office REIT Inc trades at $2.11 (market cap $119.79M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 85.6× Orion Office REIT Inc's market cap, and Orion Office REIT Inc pays a 3.81% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Orion Office REIT Inc for 34 Days on average.
| GMED | ONL | |
|---|---|---|
Market Cap | $10.25B | $119.79M |
Volume | 1,108,124 | 378,596 |
Sector | Health | Real Estate |
52-Week High | $96.82 | $3.00 |
52-Week Low | $58.33 | $1.93 |
Typical Hold Time | 0 Days | 34 Days |
Enterprise Value | $9.76B | $536.73M |
Dividend Yield | — | 3.81% |
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
ONL trades at $2.10, down 2.33% today, with a bearish technical signal from moving averages. The company shows declining revenue from $208M in 2022 to $148M in 2025 and persistent net losses, though Q2 2026 EPS beat expectations. Valuation metrics appear mixed with low P/S (0.84) and P/B (0.19) ratios but negative profitability margins. Analyst consensus is evenly split between Buy and Hold ratings.
The outlook remains challenging due to ongoing revenue declines and negative margins, though the deep discount to book value and recent earnings beat offer potential upside. Key risks include high debt levels, weak office property demand, and sustained cash flow pressures. Investors should weigh the value proposition against fundamental weaknesses.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased primarily on a single-tenant net lease basis to creditworthy clients.
Read more on ONL →